What topics does this cannabis study cover?

This study covers research on: Endocannabinoid, Inflammation, Neuroprotection.

Where was this research published?

Published in International immunopharmacology on October 14, 2026.

Endocannabinoid Inflammation Neuroprotection

Mouse and cell studies link CB2 activation with less stroke injury and…

Q: What did this research study find?

In a **mouse photothrombotic stroke model**, selective *CB2* activation with HU-308 was reported to reduce infarct volume and improve neurological outcome.

Selective CB2 receptor activation attenuates neuroinflammation and preserves immune responsiveness after photothrombotic stroke.

International immunopharmacology • October 14, 2026 • Highly Relevant

🤖

AI Summary

This abstract-based summary covers a study asking whether activating the CB2 cannabinoid receptor can reduce brain inflammation and preserve immune responses after stroke. Researchers used a photothrombotic stroke model in male mice, comparing vehicle with cannabinoid receptor drugs, including the selective CB2 agonist HU-308. They also tested HU-308 in cultured microglia. This was animal and cell research, not a human clinical trial.

In mice, non-selective receptor activation and selective CB2 activation were reported to improve neurological outcomes and reduce infarct size; blocking CB2 abolished the protection from non-selective activation. HU-308 also reduced stroke-associated inflammatory signals and preserved a measure of immune-cell response to an LPS challenge. In cultured microglia, it reduced TNF release under inflammatory conditions. The abstract does not provide numerical effect sizes. Because the work used a mouse stroke model and cell culture, it cannot establish whether these effects occur in people or whether CB2 activation is a safe or effective stroke treatment.

💡 Key Findings

In a mouse photothrombotic stroke model, selective CB2 activation with HU-308 was reported to reduce infarct volume and improve neurological outcome.

Good

75%

Blocking CB2 abolished the protection reported with non-selective cannabinoid receptor activation, supporting a role for CB2 in those mouse-model effects.

Good

75%

HU-308 suppressed stroke-associated TNF and IL-6 expression in the ischemic hemisphere and preserved leukocyte adhesion after an LPS challenge following stroke.

Good

70%

In cultured microglia, HU-308 reduced TNF release under inflammatory conditions; these cell findings do not establish an effect in humans.

Good

65%

📄 Original Abstract

Ischemic stroke triggers neuroinflammation that can drive CNS injury-induced immunodepression syndrome (CIDS), a peripheral immunosuppressive state associated with increased infection risk. The endocannabinoid system, particularly cannabinoid receptor type 2 (CB2), represents a promising immunomodulatory target because of its anti-inflammatory actions and limited psychoactive liability. In this study, we investigated whether CB2 receptor activation confers neuroprotection and preserves systemic immune responsiveness in a murine photothrombotic stroke (PTS) model. Male C57BL/6 mice underwent PTS or sham surgery and were treated before stroke induction with the non-selective CB1/CB2 agonist WIN-55212, receptor antagonists, the selective CB2 agonist HU-308, or vehicle. Neurological deficits, infarct volume, cerebral inflammatory gene expression, and intestinal leukocyte-endothelial interactions following lipopolysaccharide (LPS) challenge were assessed using Neuroscore, TTC staining, RT-qPCR, and intravital microscopy. SIM-A9 microglia were used to evaluate the effects of HU-308 on viability and cytokine release under inflammatory conditions. PTS induced a CIDS-like phenotype characterized by reduced baseline leukocyte rolling and a markedly blunted leukocyte adhesion response following LPS challenge. Non-selective cannabinoid receptor activation improved neurological scores and reduced infarct size, while CB2 blockade abolished this protection. Selective CB2 activation with HU-308 reduced infarct volume, improved neurological outcome, and suppressed stroke-associated TNF and IL-6 expression in the ischemic hemisphere. In vitro, HU-308 reduced TNF release from LPS-stimulated microglia, while IL-4 enhanced microglial viability and IL-10 production. Importantly, HU-308 preserved leukocyte adhesion after LPS challenge following stroke, suggesting maintained peripheral immune responsiveness. These findings identify CB2 receptor activation as a promising neuroimmune strategy that limits acute stroke injury while attenuating the development of CIDS.

Paper Type

📄 Research

Publication

Journal: International immunopharmacology
Published: October 14, 2026
PMID: 42874176
DOI: 10.1016/j.intimp.2026.117539

Authors (6)

Bashir Bietar Department of Critical Care, Faculty of Medicine, Dalhousie University, 1276 South Park St, Rm 379 Bethune Building Halifax, Nova Scotia, B3H 2Y9, Canada; Department of Pharmacology, Faculty of Medicine, Dalhousie University, 5850 College Street, Halifax, Nova Scotia, B3H 4R2, Canada. Electronic address: bashir.bietar@dal.ca.
Sophie Tanner Faculty of Medicine, Dalhousie University, 5850 College Street, Halifax, Nova Scotia, B3H 4R2, Canada.
Pouria Abdolmohammadi Faculty of Medicine, Dalhousie University, 5850 College Street, Halifax, Nova Scotia, B3H 4R2, Canada.
Gracious Kasheke Department of Pharmacology, Faculty of Medicine, Dalhousie University, 5850 College Street, Halifax, Nova Scotia, B3H 4R2, Canada.
Juan Zhou Department of Anesthesia, Pain Management and Perioperative Medicine, Faculty of Medicine, Dalhousie University, 5850 College Street, Halifax, Nova Scotia, B3H 4R2, Canada.
+1 more authors